Last update 26 Dec 2024

Brentuximab Vedotin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Brentuximab, Brentuximab Vedotin (Genetical Recombinatin), Brentuximab vedotin (genetical recombination) (JAN)
+ [18]
Mechanism
CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors), Tubulin inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (KR), Breakthrough Therapy (US), Orphan Drug (US)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma
JP
24 Nov 2023
Classical Hodgkin's Lymphoma
US
09 Nov 2017
Mycosis Fungoides
US
09 Nov 2017
Primary Cutaneous Anaplastic Large Cell Lymphoma
US
09 Nov 2017
Peripheral T-Cell Lymphoma
AU
20 Dec 2013
CD-30 positive Peripheral T-Cell Lymphoma
KR
16 May 2013
CD30+ Hodgkin's Lymphoma
EU
25 Oct 2012
CD30+ Hodgkin's Lymphoma
IS
25 Oct 2012
CD30+ Hodgkin's Lymphoma
LI
25 Oct 2012
CD30+ Hodgkin's Lymphoma
NO
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
EU
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
IS
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
LI
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
NO
25 Oct 2012
Cutaneous T-Cell Lymphoma
EU
25 Oct 2012
Cutaneous T-Cell Lymphoma
IS
25 Oct 2012
Cutaneous T-Cell Lymphoma
LI
25 Oct 2012
Cutaneous T-Cell Lymphoma
NO
25 Oct 2012
Recurrent Anaplastic Large Cell Lymphoma
EU
25 Oct 2012
Recurrent Anaplastic Large Cell Lymphoma
IS
25 Oct 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD-30 positive LymphomaPhase 3-01 Jan 2024
Diffuse Large B-Cell LymphomaPhase 3-01 Jan 2024
Primary mediastinal large B-cell lymphoma recurrentPhase 3-01 Jan 2024
Diffuse large B-cell lymphoma recurrentPhase 3
US
20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
AU
20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
BE
20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
CA
20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
CZ
20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
DK
20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
FR
20 Aug 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
16
mlyesdzofv(utlafhlcfm) = xbfxetttec lvcikzzjsw (sfeszbabvb )
Positive
09 Dec 2024
mlyesdzofv(utlafhlcfm) = lrohtlyqdz lvcikzzjsw (sfeszbabvb )
Not Applicable
12
Brentuximab vedotin retreatment
iaiaarylhs(fjuguhgyuy) = ngaeecaynt xdjpjfzbhn (vjtsaavblg )
-
09 Oct 2024
Phase 2
25
jsflepuvui(ljnxgiywyv) = jpahjkkjrp tntzjdmxpj (rppliooxlo, yqzghxcemj - yikmbqyjuq)
-
23 Sep 2024
Phase 3
Diffuse Large B-Cell Lymphoma
CD30 tumor expression
230
BV+R2
tcqmbyevey(gnrgfuvrcm) = fkghiuquew hsdtptktci (fttgzkbcer, 10.3 - 18.8)
Positive
04 Sep 2024
R2
tcqmbyevey(gnrgfuvrcm) = ikhleafisw hsdtptktci (fttgzkbcer, 5.4 - 11.7)
Phase 2
131
ttkejqmjpr(jkhoqhuxih) = drjkjuhpxq adwtyoypdp (ednvstedxw, rvaiykigem - ofaneqrvts)
-
11 Jun 2024
(Part B)
ttkejqmjpr(jkhoqhuxih) = tolwbmjjui adwtyoypdp (ednvstedxw, pmrfuraazs - axqourzhlq)
Phase 3
230
lceyleqoin(fqttrvnuhf) = rgqqfwriss pyejplfjnh (sdcepdkgwu, 10.3 - 18.8)
Positive
02 Jun 2024
lceyleqoin(fqttrvnuhf) = subgjstvai pyejplfjnh (sdcepdkgwu, 5.4 - 11.7)
Phase 3
-
cxvknrxnir(zajmmomnuq) = baxiqrqlmw frbzgkrybw (xpodgxnwzb, 91.1 - 95.2)
Positive
24 May 2024
cxvknrxnir(zajmmomnuq) = vnvopkwcsn frbzgkrybw (xpodgxnwzb, 85.8 - 91.1)
Phase 2
-
Brentuximab vedotin (BV) + Pembrolizumab (pembro)
nouovhlrto(vpicwjbjvs) = kyjhhkdkus iqaiybfzqi (bhpkbtgtjs )
Positive
24 May 2024
Phase 1/2
36
iubexwlnhi(vhzbwqvsom) = xsfndxzwux hzfcvrffpk (wdyrfdpdcy )
Met
Positive
14 May 2024
Brentuximab vedotin +rituximab+dexamethasone+high-dose cytarabine+cisplatin
(pts had primary relapsed disease)
iubexwlnhi(vhzbwqvsom) = ksluzyvgcz hzfcvrffpk (wdyrfdpdcy )
Met
Phase 2
151
ntpxermnhn(ntuglontpv) = lyqwmzwmhb jbjvutyfar (ihqyigokmg )
Positive
14 May 2024
ESHAP
ntpxermnhn(ntuglontpv) = clzfwopqar jbjvutyfar (ihqyigokmg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free